The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: Comparison with aripiprazole, ziprasidone, bifeprunox and F15063

European Journal of Pharmacology

Volumn 592, Issue 1-3, 2008, Pages 160-166

  Assié, Marie Bernadette ^a   Carilla Durand, Elisabeth ^a   Bardin, Laurent ^a   Maraval, Mireille ^a   Aliaga, Monique ^a   Malfètes, Nathalie ^a   Barbara, Michèle ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

(rat); 5 HT1A receptor; Antipsychotic; Dopamine D2 receptor; F15063; Plasma corticosterone; Plasma glucose

Indexed keywords

(3 EXO) 8 BENZOYL N [(7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL)METHYL] 8 AZABICYCLO[3.2.1]OCTANE 3 METHANAMINE; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; ARIPIPRAZOLE; BENZYLAMINE DERIVATIVE; BICYCLO[3.2.1]OCTANE DERIVATIVE; BIFEPRUNOX; CLOZAPINE; CORTICOSTERONE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; F 15063; GLUCOSE; HALOPERIDOL; N [(2,2 DIMETHYL 2,3 DIHYDROBENZOFURAN 7 YLOXY)ETHYL] 3 (CYCLOPENT 1 ENYL)BENZYLAMINE; OLANZAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SSR 181507; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOSTERONE RELEASE; DRUG DOSE COMPARISON; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BENZOFURANS; BENZOXAZOLES; BENZYLAMINES; BLOOD GLUCOSE; CLOZAPINE; CORTICOSTERONE; CYCLOPENTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; PIPERAZINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; THIAZOLES;

EID: 49749133879     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.105     Document Type: Article

References (56)

1. Abi-Dargham A., and Krystal J. Serotonin receptors as targets of antipsychotic medications. In: Lidow M.S. (Ed). Neurotransmitter receptors in actions of antipsychotic medications (2000), CRC Press, Boca Raton 79-107
2. Assié M.-B., Ravailhe V., Faucillon V., and Newman-Tancredi A. Contrasting contribution of 5-HT1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther. 315 (2005) 265-272
3. Auclair A.L., Kleven M.S., Besnard J., Depoortère R., and Newman-Tancredi A. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 31 (2006) 1900-1909
4. Barbaccia M.L., Affricano D., Purdy R.H., Maciocco E., Spiga F., and Biggio G. Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology 25 (2001) 489-497
5. Barbato L.M., Potkin S.G., Heisterberg J., Yeung P.P., and Shapira N.A. A randomized, double-blind, placebo-controlled study of bifeprunox, a partial dopamine D2 receptor agonist, in patients with acute exacerbations of schizophrenia. Neuropsychopharmacology 31 (suppl1), S251. (2006)
6. Bardin L., Auclair A., Kleven M.S., Prinssen E.P., Koek W., Newman-Tancredi A., and Depoortere R. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav. Pharmacol. 18 (2007) 103-118
7. Bergman R.N., and Ader M. Atypical antipsychotics and glucose homeostasis. J. Clin. Psychiatry 66 (2005) 504-514
8. Blier P., and Ward N.M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol. Psychiatry 53 (2003) 193-203
9. Bourin M., Debelle M., Heisterberg J., Josiassen M.K., Buch Østergard J., Barbato L.M., and Yeung P.P. Long-term efficacy and safety of bifeprunox in patients with schizophrenia: a 6-month, placebo-controlled study. Neuropsychopharmacology 31 (suppl1), S187. (2006)
10. Bruins Slot L.A., Kleven M.S., and Newman-Tancredi A. Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49 (2005) 996-1006
11. Casey D., Barbato L.M., Heisterberg J., Yeung P.P., and Shapira N.A. Efficacy and safety of bifeprunox in the treatment of patients with acute exacerbations of schizophrenia: results of a dose-finding study. Neuropsychopharmacology 31 (suppl1), S119. (2006)
12. Celada P., Puig M., Amargós-Bosch M., Adell A., and Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J. Psychiatry Neurosci. 29 (2004) 252-265
13. Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res. Rev. 18 (1993) 1-32
14. Claustre Y., De Peretti D., Brun P., Gueudet C., Allouard N., Alonso R., Lourdelet J., Oblin A., Damoiseau G., Françon D., Suaud-Chagny M.F., Steinberg R., Sevrin M., Schoemaker H., George P., Soubrié P., and Scatton B. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. I: neurochemical and electrophysiological profile. Neuropsychopharmacology 28 (2003) 2064-2076
15. Cohrs S., Pohlmann K., Guan Z., Jordan W., Meier A., Huether G., Ruther E., and Rodenbeck A. Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects. Psychopharmacology 174 (2004) 414-420
16. Cohrs S., Roher C., Jordan W., Meier A., Huether G., Wuttke W., Ruther E., and Rodenbeck A. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology 185 (2006) 11-18
17. Cosi C., Carilla-Durand E., Assié M.-B., Ormière A.-M., Maraval M., Leduc N., and Newman-Tancredi A. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur. J. Pharmacol. 535 (2006) 135-144
18. Czyrak A., Czepiel K., Mackowiak M., Chocyk A., and Wedzony K. Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res. 989 (2003) 42-51
19. De Hert M.A., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., and Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 83 (2006) 87-93
20. Depoortère R., Boulay D., Perrault G., Bergis O., Decobert M., Françon D., Jung M., Simiand J., Soubrié P., and Scatton B. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28 (2003) 1889-1902
21. Depoortère R., Auclair A., Bardin L., Bruins Slot L.A., Kleven M.S., Colpaert F.C., Vacher B., and Newman-Tancredi A. F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III) Profile in tests predictive of activity against cognitive deficits and negative symptoms of schizophrenia. Br. J. Pharmacol. 151 (2007) 266-277
22. Depoortère R., Bardin L., Auclair A., Kleven M.S., Prinssen E.P.M., Colpaert F.C., Vacher B., and Newman-Tancredi A. F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: II) Profile in tests predictive of activity against positive symptoms of schizophrenia. Br. J. Pharmacol. 151 (2007) 253-265
23. Diaz-Mataix L., Scorza M.C., Bortolozzi A., Toth M., Celada P., and Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 25 (2005) 10831-10843
24. Dwyer D.S., and Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol. Biochem. Behav. 75 (2003) 255-260
25. Hajduch E., Rencurel F., Balendran A., Batty I.H., Downes C.P., and Hundal H.S. Serotonin (5-Hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J. Biol. Chem. 274 (1999) 13563-13568
26. Harvey P.D., and Bowie C.R. Cognitive deficits in schizophrenia: early course and treatment. Clin. Neurosci. Res. 3 (2003) 17-22
27. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., and Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32 (2007) 289-297
28. Ichikawa J., and Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiatry Clin. Neurosci. 249 (1999) 90-98
29. Ichikawa J., and Meltzer H.Y. The effect of serotonin1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res. 858 (2000) 252-263
30. Invernizzi R.W., Cervo L., and Samanin R. 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27 (1988) 515-518
31. Kelder D., and Ross S.B. Long lasting attenuation of 8-OH-DPAT-induced corticosterone secretion after a single injection of a 5-HT1A receptor agonist. Naunyn-Schmiedeberg's Arch. Pharmacol. 346 (1992) 121-126
32. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., and Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28 (2003) 519-526
33. Levy A.D., and Van de Kar L.D. Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants. Life Sci. 51 (1992) 83-94
34. Lin E.J., Lee N.J., Slack K., Karl T., Duffy L., O'brien E., Matsumoto I., Dedova I., Herzog H., and Sainsbury A. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology 51 (2006) 1129-1136
35. Mauler F., Fahrig T., Horváth E., and Jork R. Inhibition of evoked glutamate release by the neuroprotective 5-HT1A receptor agonist BAY × 3702 in vitro and in vivo. Brain Res. 888 (2001) 150-157
36. McCreary A.C., Glennon J.C., Ashby C.R., Meltzer H.Y., Li Z., Reinders J.H., Hesselink M.B., Long S.K., Herremans A.H., van Stuivenberg H., Feenstra R.W., and Kruse C.G. SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4-[5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug. Neuropsychopharmacology 32 (2007) 78-94
37. Meier A., Neumann A.C., Jordan W., Huether G., Rodenbeck A., Ruther E., and Cohrs S. Ziprasidone decreases cortisol excretion in healthy subjects. Br. J. Clin. Pharmacol. 60 (2005) 330-336
38. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors : their key role in drugs to treat schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
39. Moss L.E., Neppe V.M., and Drevets W.C. Buspirone in the treatment of tardive dyskinesia. J. Clin. Psychopharmacol. 13 (1993) 204-209
40. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 13 (2008) 27-35
41. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
42. Newman-Tancredi A., Assié M.-B., Leduc N., Ormière A.-M., Danty N., and Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implication for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 1-16
43. Newman-Tancredi A., Assié M.-B., Martel J.C., Cosi C., Bruins Slot L.A., Palmier C., Rauly-Lestienne I., and Cussac D. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: I) in vitro, receptor affinity and efficacy profile. Br. J. Pharmacol. 151 (2007) 237-252
44. Newman-Tancredi A., Cussac D., and Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr. Opin. Investig. Drugs 8 (2007) 539-554
45. Prinssen E.P.M., Colpaert F.C., and Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur. J. Pharmacol. 453 (2002) 217-221
46. Przegalinski E., Budziszewska B., Warchol Kania A., and Blaszczynska E. Stimulation of corticosterone secretion by the selective 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat. Pharmacol. Biochem. Behav. 33 (1989) 329-334
47. Putignano P., Pecori G.F., and Cavagnini F. Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome. J. Endocrinol. Investig. 27 (2004) 969-974
48. Rapaport M., Barbato L.M., Heisterberg J., Yeung P.P., and Shapira N.A. Efficacy and safety of bifeprunox versus placebo in the treatment of patients with acute exacerbations of schizophrenia. Neuropsychopharmacology 31 (suppl1), S184. (2006)
49. Robinson K.A., Yacoub Wasef S.Z., and Buse M.G. At therapeutic concentrations, olanzapine does not affect basal or insulin-stimulated glucose transport in 3T3-L1 adipocytes. Prog. Neuro-psychopharmacol. Biol. Psychiatry 30 (2006) 93-98
50. Rollema H., Lu Y., Schmidt A.W., and Zorn S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur. J. Pharmacol. 338 (1997) R3-R5
51. Sovner R., and Parnell-Sovner N. Use of buspirone in the treatment of schizophrenia. J. Clin. Psychopharmacol. 9 (1989) 61-62
52. Sumiyoshi T., Matsui M., Nohara S., Yamashita I., Kurachi M., Sumiyoshi C., Jayathilake K., and Meltzer H.Y. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry 158 (2001) 1722-1725
53. Sumiyoshi T., Matsui M., Yamashita I., Nohara S., Kurachi M., Uehara T., Sumiyoshi S., Sumiyoshi C., and Meltzer H.Y. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol. Psychiatry 49 (2001) 861-868
54. Vestri H.S., Maianu L., Moellering D.R., and Garvey W.T. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32 (2007) 765-772
55. Wedzony K., Mackowiak M., Zajaczkowski W., Fijal K., Chocyk A., and Czyrak A. WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 23 (2000) 547-559
56. Wolf W. DU-127090. Curr. Opin. Investig. Drugs 4 (2003) 72-76